Janet Shipley
Has grant
Group Leader, Sarcoma Molecular Pathology
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Recent Grants
Grant: Open
Unravelling Transition processes between Epithelial and Mesenchymal cells in Desmoplastic Small Round Cell Tumours to Improve Treatment options
Open Date: 2026-01-01
Close Date: 2027-12-01
Grant: Open
Development Of Natural Killer Cell Immunotherapy for Paediatric Rhabdomyosarcoma
Open Date: 2026-01-01
Close Date: 2029-01-01
Grant: Open
Epigenetic therapies to enhance the immune response of paediatric rhabdomyosarcomas
Open Date: 2024-01-01
Close Date: 2027-01-01
Grant: Open
Facilitating Current and Future Molecular Biological Studies of Rhabdomyosarcoma (RMS) through Improved Management of Sample Collection and Data
Open Date: 2024-01-01
Close Date: 2027-01-01
Grant: Open
Defining plasticity in RhabdoMyoSarcoma (RMS) cells: A new approach to derive new treatments that prevent or treat relapse
Open Date: 2023-01-01
Close Date: 2027-01-01
Articles (22)
Year:
2026
Year:
2026
Desmoplastic small round cell tumor (DSRCT) is an aggressive sarcoma subtype that is driven by the EWS–WT1 chimeric transcription factor. The prognosis for DSRCT is poor, and major advances in treating DSRCT have not occurred for over two decades. To identify effective therapeutic approaches to target DSRCT, we conducted a high-throughput drug sensitivity screen in a DSRCT cell line assessing chemosensitivity profiles for 79 small-molecule inhibitors. DSRCT cells were sensitive to PARP inhibitors (PARPi) and ataxia–telangiectasia and Rad3–related inhibitors (ATRi), as monotherapies and in combination. These effects were recapitulated using multiple clinical PARPi and ATRi in three biologically distinct, clinically relevant models of DSRCT, including cell lines, a patient-derived xenograft–derived organoid model, and a cell line–derived xenograft mouse model. Mechanistically, exposure to a combination of PARPi and ATRi caused increased DNA damage, G2–M checkpoint activation, micronuclei accumulation, replication stress, and R-loop formation. EWS–WT1 silencing abrogated these phenotypes and was epistatic with exogenous expression of the R-loop resolution enzyme RNase H1 in reversing sensitivity to PARPi and ATRi monotherapies. The combination of PARPi and ATRi also induced EWS–WT1–dependent cell-autonomous activation of the cyclic GMP–AMP synthase–stimulator of IFN genes innate immune pathway and cell-surface expression of PD-L1. Taken together, these findings point toward a role for EWS–WT1 in generating R-loop–dependent replication stress that leads to a targetable vulnerability, providing a rationale for the clinical assessment of PARPi and ATRi in DSRCT. Significance: EWS–WT1, the unique oncogenic driver of desmoplastic small round cell tumors, confers sensitivity to PARP and ATR inhibitors, supporting the potential of these drugs in treating patients with this aggressive sarcoma subtype.
Year:
2025
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and young people. Despite the advances in multimodality treatment over recent decades through successive prospective clinical trials, improved rates of survival for patients are mainly limited to those with localised RMS without adverse biologic features. Current clinicopathologic prognostic factors include PAX3(7)::FOXO1 fusion status, the site of primary disease, the pre-chemotherapy extent of disease (including microscopic vs. macroscopic residual disease, locoregional nodal involvement and metastatic status), tumour size and patient age. These factors are used to stratify patients into prognostic risk groups that guide treatment intensity and duration. Risk stratification algorithms are evolving, supported by advances in molecular biology and cancer genomics. In this review we focus on the poorest prognostic groups of paediatric-type RMS (i.e., Very High Risk or relapsed/progressive disease). These include patients whose tumours harbour poor biological characteristics such as PAX3(7)::FOXO1 fusion-positive tumours with locoregional nodal involvement and tumours harbouring other poor-risk genetic variants (particularly MYOD1 and TP53 variants); adolescent and young adult patients; newly diagnosed patients with metastatic RMS; and patients with relapsed and refractory disease. Here we aim to describe the clinical characteristics of these patients, outline current standard multimodality treatments in the context of sequential international clinical trials across the major cooperative groups and summarise emerging novel diagnostic and therapeutic approaches.
Year:
2025
Year:
2025
Year:
2025
Background Patients with PAX3/7‐FOXO1 fusion‐negative rhabdomyosarcomas (fnRMS) harbouring the rare L122R MYOD1 mutation have significantly poorer prognosis than other fnRMS. We undertook a detailed clinicopathological evaluation of a cohort of patients with MYOD1 mutat ed fnRMS in order to improve risk stratification and treatment options. Procedure Histological, mutational and clinical data from a cohort of patients with MYOD1 mutant RMS treated in Europe were analysed. Results Thirty‐two cases with mutant MYOD1 RMS were identified from patients enrolled in sequential European rhabdomyosarcoma clinical trials from 1992 to 2022 ( n = 22) and non‐trial cohorts ( n = 10). Thirty cases had the recurrent L122R missense mutation, one case harboured a K124E mutation and one case had a truncating mutation (S63X). Increased MyoD1 and reduced MYF4 immunostaining were consistent features of MYOD1 L122R ‐mutated RMS. Applying the risk stratification of the European paediatric Soft tissue sarcoma Study Group (E p SSG) RMS2005 trial, among 20 localised RMS cases that could be assigned a risk category, one was Very High Risk, 13 were High Risk and six were Standard Risk. Eight patients had distant metastases at diagnosis. Of the 25 patients with adequate clinical follow‐up data, 15/25 (60%) patients had an event at a median time of 9 months (12/15 included failure of local control) and 13/25 (52%) died of disease. Conclusion This MYOD1 mutant cohort demonstrates increased MYOD and reduced MYF4 immunostaining, high risk of local failure and poor survival in agreement with other studies. Increased treatment intensity and improved local control should be considered for these patients.
Year:
2025
A5/158-vc-MMAE decreases the number and size of spontaneous metastases. Continuation of Fig. 5 . A, Ex vivo IVIS imaging and quantification of lungs at endpoint (mean values ± SEM, two-sided Mann–Whitney U test). B, Representative FFPE lung sections stained for lamin A/C at 3 levels 150 μm apart. Scale bar, 100 μm. C, Quantification of the number of metastatic lung lesions, average area of lung lesions, and % metastatic area of lung lesions (mean of three sections per mouse). Data shown are mean values ± SEM; number of lung lesions, two-sided Mann–Whitney U test; average area of lung lesions and metastatic tumor area, two-sided unpaired t test. D, Proportion of mice with liver metastases. E, Proportion of mice with lymph node metastases.
Year:
2025
Endo180 protein expression in sarcoma cell lines compared to epithelial cancer cells by immunofluorescence. Additionally, this figure shows the isotype control antibody conjugated to AlexaFluor 488 is not internalized into Endo180 expressing sarcoma cell lines and is not trafficked to the lysosome.
Year:
2025
Endo180 expressing cell lines are sensitive to A5/158-vc-MMAE. A, Schematic representation of an antibody conjugated to an MMAE payload (green) via a cleavable valine–citrulline linker (pink). B, Endo180-positive and Endo180-negative cell lines were treated with A5/158-vc-MMAE or isotype-vc-MMAE for 72 hours. Shown are representative graphs (independent experiments n = 3) of cell viability readouts determined by CellTiter-Glo. Data are normalized to untreated cells ( n = 3 wells per condition, mean values ± SEM).
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Collaborators (37)
Christopher Lord
Professor of Cancer Genomics
Institute of Cancer Research
Clare Isacke
Professor of Molecular Cell Biology
Institute of Cancer Research
Etienne Schwob
Senior Group Leader (DR2)
CNRS Délégation Languedoc-Roussillon
Noé Herbel
Institut Gustave Roussy
Neil Sebire
University College London
Michael Hubank
Professor of Translational Genomics
University College London
Juliet Gray
Professor of Paediatric Oncology
University of Southampton
Chris Jones
Professor of Childhood Brain Tumour Biology
Institute of Cancer Research
Sophie Postel-Vinay
Institut Gustave Roussy
Steven C. Clifford
Prof of Molecular Paediatric Oncology
Newcastle University
Zoe Walters
Professor
University of Southampton
Susanne Andrea Gatz
University of Birmingham
William Anderson
University College London
Mark Hatley
Associate Member
St. Jude Children's Research Hospital
Guy Makin
Senior Lecturer in Paediatric Oncology
The University of Manchester
Sibylle Mittnacht
University College London
Trevor A Graham
Director
Institute of Cancer Research
Sapna Oberoi
Associate Professor
University of Manitoba
Reuben Pengelly
Principal Teaching Fellow
University of Southampton
Deborah A. Tweddle
-
Ridwan Shaikh
Institute of Cancer Research
Bissan Al-Lazikani
Professor, Director of Therapeutics Data Science
The University of Texas MD Anderson Cancer Center
Roman M. Chabanon
Post-doctoral research fellow
Institut Gustave Roussy
Nathaniel Anderson
Wellcome Sanger Institute
Sally George
Institute of Cancer Research
Guillaume PINNA
Head of a High Content Screening facility
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
Richard Grundy
Professor of Paediatric Neuro-Oncology and Cancer Biology
University of Nottingham
Louis Chesler
professor
Institute of Cancer Research
Alice Piapi
University College London
Amos Burke
Professor of Paediatric Oncology and Director
University of Birmingham
Gianni Bisogno
Docenti di ruolo di Ia fascia
University of Padova
Isidro Cortes Ciriano
Research Group Leader
European Bioinformatics Institute
Andrea Sottoriva
Head
Human Technopole
Darren Hargrave
University College London
Carolin Sauer
Group Leader
Vall d'Hebron Institute of Oncology
Pamela Kearns
University of Birmingham
Meritxell B. Cutrona
Head of Platform | Patient-derived organoids for Precision Medicine
Institut Gustave Roussy
Make your next move.
Prepare your application
Review drafts before you send them.